Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders (2010 - 2026)

Northwest Biotherapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 82.66% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$45.3 million (up 47.31% YoY), while the FY2025 annual figure was -$61.5 million, up 27.84% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$3.4 million, down from $1.3 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $1.3 million in Q4 2025, with the low at -$32.9 million in Q3 2022.
• The 5-year median for Net Income towards Common Stockholders is -$18.9 million (2024), against an average of -$18.8 million.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders tumbled 844.94% in 2022, then surged 104.39% in 2025.
• Northwest Biotherapeutics' Net Income towards Common Stockholders stood at -$28.3 million in 2022, then soared by 49.4% to -$14.3 million in 2023, then slumped by 99.02% to -$28.5 million in 2024, then soared by 104.39% to $1.3 million in 2025, then sank by 371.78% to -$3.4 million in 2026.
• Business Quant data shows NWBO's Net Income towards Common Stockholders at -$3.4 million in Q1 2026, $1.3 million in Q4 2025, and -$27.2 million in Q3 2025.